Oncogenic mutations of PIK3CA in human cancers

Cell Cycle

Volumn 3, Issue 10, 2004, Pages 1221-1224

  Samuels, Yardena ^a   Velculescu, Victor E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Oncogene; p110 ; PI3K; PIK3CA; Somatic mutation

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; GEFITINIB; IMATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P110; PROTEIN P110 ALPHA; UNCLASSIFIED DRUG; WORTMANNIN;

BRAIN CANCER; BREAST CANCER; CARCINOGENESIS; COLON CANCER; DIAGNOSTIC TEST; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME SUBUNIT; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; LUNG CANCER; MULTIGENE FAMILY; ONCOGENE; PIK3CA GENE; PROTEIN DOMAIN; REVIEW; SIGNAL TRANSDUCTION;

EID: 13944284494     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.3.10.1164     Document Type: Review

References (32)

1. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
2. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655-7.
3. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: Implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17:615-75.
4. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine Phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943-7.
5. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15:356-62.
6. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995; 64:280-5.
7. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21:99-102.
8. Phillips WA St Clair F, Munday AD, Thomas RJ, Mitchell CA. Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors. Cancer 1998; 83:41-7.
9. Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, et al. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERα) via interaction between ERα and PI3K. Cancer Res 2001; 61:5985-91.
10. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003; 300:949.
11. Wang Z, Cummins JM, Shen D, Cahill DP, Jallepalli PV, Wang TL, et al. Three classes of genes mutated in colorectal cancers with chromosomal instability. Cancer Res 2004; 64:2998-3001.
12. Wang Z, Shen D, Parsons DW Bardelli A, Sager J, Szabo S, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004; 304:1164-6.
13. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304:554.
14. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004; In press.
15. Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE, et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 2004; 64:5048-50.
16. Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999; 253:239-54.
17. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327:293-7.
18. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-54.
19. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997; 275:1787-90.
20. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411:355-65.
21. Walker EH, Perisic O, Ried C, Stephens L, Williams RL. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 1999; 402:313-20.
22. Djordjevic S, Driscoll PC. Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinases. Trends Biochem Sci 2002; 27:426-32.
23. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell 2003; 4:257-62.
24. Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH, et al. The phosphatidylinositol 3′-kinase p85α gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001; 61:7426-9.
25. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418:934.
26. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002; 2:210-19.
27. Traverso G, Shuber A, Levin B, Johnson C, Olsson L, Schoetz Jr DJ, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002; 346:311-20.
28. Traverso G, Shuber A, Olsson L, Levin B, Johnson C, Hamilton SR, et al. Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet 2002; 359:403-4.
29. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344:1038-42.
30. Lynch TJ, Bell DW, Sordella R, Gurabhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39.
31. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR Mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500.
32. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in vitro and in vivo ovarian cancer models. Cancer Res 2002; 62:1087-92.